MIRA Pharmaceuticals (NASDAQ:MIRA) Cut to Sell at Wall Street Zen

by · The Markets Daily

Wall Street Zen lowered shares of MIRA Pharmaceuticals (NASDAQ:MIRA – Free Report) from a hold rating to a sell rating in a research note released on Friday morning.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA stock opened at $1.40 on Friday. The stock has a market capitalization of $26.70 million, a P/E ratio of -2.86 and a beta of 1.75. The company has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.24. MIRA Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $2.56.

MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, research analysts forecast that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MIRA. Citadel Advisors LLC purchased a new stake in shares of MIRA Pharmaceuticals during the 4th quarter worth approximately $112,000. Northern Trust Corp lifted its position in shares of MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after buying an additional 10,238 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of MIRA Pharmaceuticals during the 4th quarter worth approximately $28,000. Suncoast Equity Management lifted its position in shares of MIRA Pharmaceuticals by 356.1% during the 1st quarter. Suncoast Equity Management now owns 103,289 shares of the company’s stock worth $101,000 after buying an additional 80,645 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter worth approximately $27,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

(Get Free Report)

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

Read More